This is further supported by Vlad et al. who demonstrated that stage I or II CRC had significantly more FOXP3 + Tregs than stage III or IV tumors suggesting an anti-tumor effect (Salama et al. 2009; Vlad et al. 2015). Here, FOXP3 is linked to neoplasm.